NASHVILLE, Tenn., July 14 /PRNewswire/ -- A newly available treatment already has benefited several individuals with aggressive malignancies. Offered through NeoPlas Innovation, this regimen has arrested or eradicated tumors in more than 80% of initial patients. Director of Research Dr. Stephen Cantrell emphasized that human testing is in its early stages, but added, "These results have surprised us. This is far beyond what currently available standard treatments achieve."
Melanoma, a deadly form of malignant skin cancer, is among the diseases targeted to date. The first person treated with the investigative protocol had stage 4 melanoma and a life expectancy of eight weeks. He experienced a complete response and remains disease-free eight years later. While not all results have been this dramatic, each NeoPlas melanoma patient has had results significantly better than those with standard therapy. Eradication of tumors or long-term stability has occurred in most patients; others have seen a substantial slowing of progression.
The new protocol incorporates a unique combination of FDA-approved drugs used by millions of people for other applications. When administered alone, these drugs show some benefit against cancer, but not enough to make a difference for most patients. The combination of the medicines, however, allows lower, more tolerable dosages and provides effectiveness not seen in previous, single-drug studies.
The NeoPlas treatment disables certain abnormal cellular processes many of the aggressive malignancies share. Based on experience and relevant lab research to date, staff members expect the best results for: melanoma, pancreatic cancer, colon cancer, renal (kidney) cancer, mesothelioma, and a group of sarcomas, including osteosarcoma, chondrosarcoma and malignant fibrous histiocytoma. The regimen is not expected to have significant benefit against brain tumors.
The most notable side effect is fatigue. Most patients ne
|SOURCE NeoPlas Innovation|
Copyright©2008 PR Newswire.
All rights reserved